DIRS.INFO The most relevant business & tech news

☆ EU’s best way to close its US growth gap: growth
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

BRUSSELS, Oct 26 (Reuters Breakingviews) - The European Union would have a better chance of catching the U.S. if it aimed for growth, instead of rearranging the regulatory deck chairs. Lowering political barriers in the 27-country single market could boost investment without breaking the bank on subsidies, Jean-François van Boxmeer told Breakingviews, citing a new European Round Table for Industry report. In the telecommunications sector, the European Commission has kept four providers in most of the EU’s markets, and screens out Chinese equipment-makers over security concerns. The European Commission reckons completing the single market by 2030 would hike EU GDP by 12%, or 713 billion euros. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: François van Boxmeer, Breakingviews, van Boxmeer, Jacob Wallenberg, Rebecca Christie, George Hay, Streisand Neto Organizations: Reuters, European, Vodafone, Reuters Graphics Business, EU, European Commission, Investor, X, News Corp, Thomson Locations: BRUSSELS

☆ New-look Unilever retains its old-style opacity
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

Unilever logo is displayed on Dove soap boxes in this illustration taken on January 17, 2022. Back in 2017 Unilever fought off a Kraft Heinz (KHC.O) takeover approach by pledging a 20% operating margin; now there just isn’t a target. But it leaves a question mark over Unilever’s long-term direction. And it might leave long-term critics like fund manager Terry Smith still griping about opacity. In January Smith complained that Unilever had revealed the price tag on only three of 27 acquisitions in its Beauty and Wellbeing division over eight years.

Persons: Dado Ruvic, Hein Schumacher’s, Kraft Heinz, Alan Jope, Terry Smith, Smith, Schumacher, George Hay, Peter Thal Larsen, Oliver Taslic Organizations: Unilever, REUTERS, Reuters, Kraft, X, Thomson

☆ US growth boom tees up year-end bust
▼ + stars: | 2023-10-26 | by ( ) www.reuters.com time to read: +2 min

The latest report on the country's growth is worth celebrating, but not for too long. Household incomes after inflation and taxes fell by $71 billion in the third quarter, according to Pantheon Macroeconomics. That shrank in the third quarter, with managers flagging peak interest rates as a larger concern, leaving less in the pipeline. Yet stores spent $81 billion in excess inventory last quarter and are likely to wait to restock shelves. Last quarter’s boom should give way to a bust.

Persons: Lee Jae, LSEG, Ben Winck, Lauren Silva Laughlin, Sharon Lam Organizations: Rights, Reuters, Macroeconomics, Savings, Companies, X, Unilever, Thomson Locations: U.S

☆ Roche's $7 bln deal is pricey and partial cure
▼ + stars: | 2023-10-23 | by ( ) www.reuters.com time to read: +2 min

Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsNEW YORK, Oct 23 (Reuters Breakingviews) - Roche (ROG.S) has taken a small step towards curing its drug pipeline problem. JPMorgan analysts estimate that the drug’s U.S. sales could peak at 2.4 billion Swiss francs ($2.7 billion), but will take until 2037 to get there, assuming a 2028 launch. Analysts expect Roche’s pharmaceutical division to generate revenue of almost 45 billion Swiss francs this year, according to estimates compiled by LSEG. With expected free cash flow of around 16 billion Swiss francs this year and next, Roche can afford to buy a little more diversification.

Persons: Roche, Dado Ruvic, Thomas Schinecker, Peter Thal Larsen, Jean, Pierre Mustier, Atos, Jonathan Guilford, Aditya Sriwatsav Organizations: REUTERS, Reuters, Pfizer, U.S, New, JPMorgan, Merck, Prometheus Biosciences, Analysts, LSEG, X, News Corp, Thomson Locations: Swiss, U.S

☆ Merck’s cancer rush may spawn lower returns
▼ + stars: | 2023-10-20 | by ( ) www.reuters.com time to read: +2 min

The American drug company said on Thursday it signed a giant deal with Daiichi Sankyo (4568.T) for the rights to sell three potential drugs outside Japan. Merck will pay $4 billion upfront, up to another $1.5 billion over the next two years, and as much as $16.5 billion if the drugs pass certain sales milestones. Merck’s Keytruda accounts for about 40% of the company’s revenue, and that cancer drug might face cut-price competition before the end of the decade. The potential is giant, as these targeted therapies might eventually account for a quarter of the current oncology market. With over 100 of these drugs in clinical trials, the stampede might lead to lower-than-expected returns.

Persons: Jeff Zelevansky, Robert Cyran, Jean, Pierre Mustier, Atos, Jennifer Saba, Aditya Sriwatsav Organizations: Merck & Co, REUTERS, Reuters, Merck, Pfizer, X, News Corp, Thomson Locations: Linden , New Jersey, American, Japan

☆ Morning Bid: Bonds haunted by uncertainties old and new
▼ + stars: | 2023-10-20 | by ( ) www.reuters.com time to read: +3 min

A trader works on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 28, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsA look at the day ahead in European and global markets from Tom WestbrookIt's looking like the worst week of another bad year for bonds. Curiously, the dollar hasn't moved higher with the latest leap in yields, perhaps because currency traders see recession in the offing. Fed Chair Jerome Powell said little that markets didn't already know on Thursday, but in keeping his options open he kept the pressure on bonds. "A range of uncertainties, both old and new, complicate our task of balancing the risk of tightening monetary policy too much against the risk of tightening too little," he said.

Persons: Brendan McDermid, Tom Westbrook It's, Brent Donnelly, Jerome Powell, Joe Biden, Israel, Fed's Mester, Harker, Tom Westbrook, Edmund Klamann Organizations: New York Stock Exchange, REUTERS, Spectra Markets, MSCI's, Bank of Japan, North America ., Thomson Locations: New York City, U.S, New York, MSCI's Asia, Japan, Gaza, China, London, North America

"Anecdotally from technicians we are seeing a significant increase in interest (in the UK)," a spokesperson for Rentokil said in an emailed statement to Reuters. Rentokil Pest Control in the UK tracked a 65% increase year-on-year in recorded bedbug activity in the second quarter of 2023, versus last year. "This is when a pest technician had confirmed the activity," the spokesperson said. An activity is when a technician has been on a customer site and confirmed the presence of bedbugs. Reporting by Anchal Rana and Yadarisa Shabong in Bengaluru; editing by David EvansOur Standards: The Thomson Reuters Trust Principles.

Persons: Stephanie Lecocq, London Sadiq Khan, PoliticsJOE, Rentokil, Anchal Rana, Yadarisa, David Evans Organizations: Hygiene, REUTERS, Paris Olympics, bedbugs, Transport, Reuters, Thomson Locations: bedbugs, L'Hay, Paris, France, French, London, Rentokil Pest, Bengaluru

☆ Rentokil may be next to nibble at US listing
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Mike Blake Acquire Licensing RightsLONDON, Oct 19 (Reuters Breakingviews) - Rentokil (RTO.L) is an obvious contender to ditch its London listing in favour of the U.S. CEO Andy Ransom said that it is getting harder to win new business due to “the macroeconomic backdrop”. Rollins is valued on nearly 38 times its forward earnings, versus Rentokil which was trading on just 23 times before Thursday’s fall, according to LSEG data. With Rentokil shareholders a little ratty, Ransom may come under more pressure to consider ways of pepping up the stock, like ditching London in favour of the more highly valued U.S. market. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Mike Blake, Andy Ransom, Ransom, Rollins, Aimee Donnellan, Jean, Pierre Mustier, Atos, Larry Fink, Uncle Sam, Neil Unmack, Oliver Taslic Organizations: REUTERS, Reuters, U.S, X, News Corp, Thomson Locations: Los Angeles , California, U.S

☆ FTSE 100 gains as British banks bounce back; Rentokil rises
▼ + stars: | 2023-03-16 | by ( Shashwat Chauhan | ) www.reuters.com time to read: +2 min

UK's blue-chip FTSE 100 (.FTSE) gained 0.4%, rebounding from its steepest fall in over a year on Wednesday. British banks (.FTNMX301010) gained 1.8%, after falling 5.6% in the previous session. Rentokil Initial (RTO.L) jumped 6.1% to the top of the FTSE 100 after the pest control services provider lifted its medium-term outlook after posting a better-than-expected annual profit. The more domestically-focussed FTSE 250 midcap index (.FTMC) were subdued, though asset manager Bridgepoint Group (BPTB.L) rose 2.9% after reporting a higher revenue for 2022. Reporting by Shashwat Chauhan in Bengaluru; Editing by Savio D'Souza and Uttaresh VenkateshwaranOur Standards: The Thomson Reuters Trust Principles.

☆ Morning Bid: Trick or treat?
▼ + stars: | 2022-11-01 | by ( ) www.reuters.com time to read: +2 min

A look at the day ahead in European and global markets fromAnshuman DagaThere's a sense of cheer among investors before the Fed's mid-week rate decision as markets seem to be pricing in an expected treat from the U.S. central bank. Risk-on appetite is gradually coming back as global stocks flirt with their strongest levels in just over a month while the mighty dollar slips from a one-week high. The Fed is set to raise rates by 75 basis points for the fourth straight time, bringing the target overnight lending rate to a 3.75%-4.00% range. Analysts at BlackRock Investment Institute are, however, still underweight on stocks as they see central banks on a path to overtighten policy. Down Under, the Reserve Bank of Australia stuck with a 25 basis points rate hike as widely expected, while revising up its inflation outlook.

Search resuls for: "Rentokil"

10 mentions found